Agilent Technologies stock holds gains after strong Q3 2026 earnings and guidance raise
Published on 08/29/2026 at 10:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Agilent Technologies stock (ISIN US00846U1016) is trading solidly as of August 28, 2026, after the company delivered stronger-than-expected results for its fiscal third quarter 2026 and raised its full-year guidance, signaling healthy demand across its core analytical instruments and diagnostics markets. Per recent market data, the shares closed at $157.69 on August 28, 2026, up 1.68 percent on the day.
Q3 2026 earnings beat with higher margins
Per a recent earnings recap, Agilent reported fiscal Q3 2026 revenue of $1.88 billion, an increase of 8.1 percent year over year compared with the same quarter a year earlier. The figure exceeded analyst expectations of $1.84 billion, pointing to stronger-than-anticipated demand across the company’s key end markets.
Adjusted earnings per share for fiscal Q3 2026 came in at $1.62, beating the consensus estimate of $1.49 and rising from $1.37 in the prior-year quarter. That means adjusted EPS grew by 18.2 percent year over year, a faster pace than revenue, reflecting operating leverage and better profitability. The company also reported a net margin of 19.53 percent and a return on equity of 24.84 percent in this latest quarter, highlighting a capital-efficient business model with solid cash generation.
Full-year 2026 outlook raised after strong quarter
On the back of its fiscal Q3 2026 performance, management lifted Agilent’s full-year outlook, offering investors clearer visibility on the trajectory of earnings and revenue. The company now expects adjusted EPS for fiscal 2026 in a range of $6.18 to $6.21. This is above the previously cited analyst consensus of $6.06 for the year, implying the new midpoint is 2.0 percent higher than that prior expectation and signaling confidence in sustained demand and cost discipline.
For revenue, Agilent now projects fiscal 2026 sales of approximately $7.5 billion, compared with earlier expectations closer to $7.4 billion. Even taking the $7.5 billion figure against the $7.4 billion consensus implies growth of 1.4 percent versus prior expectations, which aligns with the company’s view that order trends, particularly in life sciences and chemical analysis, are improving. In addition, Agilent has set specific guidance for its fiscal Q4 2026 adjusted EPS in the range of $1.71 to $1.74, which, if achieved, would represent a sequential step-up from the latest quarter’s $1.62 and underscore the company’s confidence into the end of the fiscal year.
Stock performance and valuation context
Recent quote data as of August 28, 2026, shows Agilent shares closing at $157.69, with an after-hours indication of $157.50. At that closing level, the stock’s year-to-date total return stands at 16.58 percent compared with 12.94 percent for the S&P 500 over the same period, indicating Agilent has outperformed the broader U.S. equity benchmark by 3.64 percentage points in 2026 so far. On a one-year basis, the stock’s total return of 33.92 percent versus 19.28 percent for the S&P 500 highlights an even larger 14.64 percentage-point outperformance.
The trailing three-year total return picture is more nuanced: Agilent’s 34.80 percent total return over that span is lower than the S&P 500’s 75.48 percent, suggesting that while the stock has delivered solid absolute gains, investors who held over the past three years would have seen better performance in the broader index. The recent acceleration in returns over the last twelve months, however, indicates that the market has rewarded the company’s latest earnings momentum and guidance increases, narrowing part of that longer-term performance gap.
Given fiscal 2026 adjusted EPS guidance at a midpoint of $6.195 (the midpoint of the $6.18 to $6.21 range), the recent $157.69 share price implies a forward price-to-earnings ratio of about 25.5 times. That multiple reflects the market’s willingness to pay a premium for consistent mid-single to high-single-digit revenue growth, expanding margins, and a strong competitive position in life sciences, diagnostics, and chemical analysis instrumentation. For investors, the key question is whether Agilent can sustain high-teens EPS growth, as evidenced by the jump from $1.37 to $1.62 in the latest quarter, against this valuation backdrop.
Earnings momentum and guidance detail
The fiscal Q3 2026 results show that Agilent’s revenue growth of 8.1 percent year over year, from a base where the prior-year quarter delivered $1.74 billion (derived by reversing the growth rate), is driven by a combination of volume expansion and incremental pricing. The adjusted EPS increase from $1.37 to $1.62 reflects 25 cents of per-share improvement, with a portion likely attributable to higher gross margins and disciplined operating expenses, as implied by the reported improvement in operating profit and margins.
Looking ahead to fiscal Q4 2026, the adjusted EPS guidance range of $1.71 to $1.74 suggests potential growth versus the $1.62 reported in Q3 2026, even if revenue growth moderates. If Agilent were to deliver the midpoint of that Q4 range, adjusted EPS for that quarter would be 5.6 percent above the Q3 level. Combined with the full-year guidance, this indicates management expects continued demand strength and margin resilience in its high-value instruments, consumables, and services portfolio.
Market reaction and institutional interest
The combination of a Q3 earnings beat, raised full-year guidance, and an above-market year-to-date total return has supported Agilent’s share price into late August 2026. The stock’s closing level of $157.69 on August 28, 2026, represents a gain compared with earlier periods in the year and places the stock not far from recent highs referenced by market data providers. Institutional investors appear to be responding to the company’s execution, with recent disclosures from investment managers highlighting new or increased positions referencing the latest quarter.
For retail investors, the key takeaway is that Agilent’s earnings profile has become more robust, with revenue growth outpacing many traditional industrial names and EPS expanding faster than sales. The company’s decision to raise its fiscal 2026 outlook after Q3 2026 results indicates that management sees favorable trends in spending on analytical instruments, software, and diagnostic solutions across pharmaceutical, biotech, and industrial customers, even in a macro environment that has been mixed for capital equipment vendors.
Agilent’s LC-MS systems support lab productivity
One representative product area that illustrates Agilent’s competitive positioning is its liquid chromatography-mass spectrometry (LC-MS) systems. These systems are widely used in pharmaceutical research, clinical laboratories, environmental testing, and food safety analysis to separate, identify, and quantify complex mixtures of molecules with high precision. By integrating advanced liquid chromatography technology with high-resolution mass spectrometry, Agilent’s LC-MS platforms enable scientists to detect trace levels of contaminants, characterize biomolecules, and monitor manufacturing processes efficiently.
Beyond the hardware, Agilent complements its LC-MS systems with software for data analysis, compliance support, and workflow automation. This combination of instruments, software, and services helps laboratories improve throughput and reproducibility while meeting stringent regulatory requirements. In practice, that means customers can shorten analytical run times, increase the number of samples processed per day, and generate more reliable data for decision-making in drug development or quality control, which in turn supports recurring revenue through consumables and service contracts.
Stock level and investor perspective
Agilent Technologies is listed on the New York Stock Exchange under the ticker symbol A, trading in U.S. dollars. As of the close on August 28, 2026, the share price stood at $157.69, with an after-hours indication of $157.50, framing the latest results and guidance within a market capitalization that reflects investors’ confidence in the company’s earnings trajectory and industry position.
Fact box
Company: Agilent Technologies, Inc.
ISIN: US00846U1016
Ticker: A
Exchange: New York Stock Exchange (NYSE)
Price (as of August 28, 2026, 4:02 p.m. ET): $157.69 USD
Sector / Industry: Life sciences tools and services / analytical instruments
Index membership: S&P 500
